Human TP63 (Tumor Protein 63) - Recombinant Protein
Beta LifeScience
SKU/CAT #: BLT-05166P

SDS-PAGE analysis of Human TP63 (Tumor Protein 63) - Recombinant Protein, CAT# BLT-05166P, showing >90% purity under 15% SDS-PAGE (Reduced)
Human TP63 (Tumor Protein 63) - Recombinant Protein
Beta LifeScience
SKU/CAT #: BLT-05166P
Regular price
$59500
$595.00
Sale price$44500
$445.00Save $150
/
Quantity Pricing
Pack Size | Price (USD) |
---|---|
500 µg | $1,030 (Fall Promotion) |
1 mg | $1,870 (Fall Promotion) |
For direct online orders, quantity pricing will be displayed in cart when you add 5x100ug or 10x100ug
Submit an inquiry or email inquiry@betalifesci.com for a customization request or bulk order quote.
Connect with us via the live chat in the bottom corner to receive immediate assistance.
Product Overview
Product Name | Recombinant Human P63 / TP63 / Tumor p63 Protein |
Product Overview | This recombinant human P63 / TP63 / Tumor p63 protein includes amino acids 1-680aa of the target gene is expressed in Baculovirus-Insect Cells.The protein is supplied in lyophilized form and formulated in phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5% trehaloseprior to lyophilization. |
Target Uniprot Id | Q9H3D4 |
Recommended Name | Tumor protein 63 |
Gene Name | TP63 |
Synonyms | AIS;B(p51A);B(p51B);EEC3;KET;LMS;NBP;OFC8;p40;p51;p53CP;p63;p73H;p73L;RHS;SHFM4;TP53CP;TP53L;TP73L |
Species | Human |
Predicted Molecular Mass | 105 kDa |
Expression System | Insect Cell |
Expression Range | 1-680aa |
Tag | N-His&GST |
Purity | >90% |
Formulation | Lyophilized |
Buffer | Phosphate buffered saline (pH7.4) containing 0.01% sarcosyl, 5%Trehalose |
Storage Condition | 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
Reconstitution Instruction | Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
Applications | Positive Control; Immunogen; SDS-PAGE; WB |
Research Area | Apoptosis |
Target Function | Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. |
Subcellular Location | Nucleus. |
Protein Family | P53 family |
Associated Diseases | Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome); Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC); Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3); Split-hand/foot malformation 4 (SHFM4); Limb-mammary syndrome (LMS); Ectodermal dysplasia, Rapp-Hodgkin type (EDRH); Non-syndromic orofacial cleft 8 (OFC8) |
Tissue Specificity | Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type i |